Nuo Therapeutics, Inc. operates as a regenerative therapies company that develops, commercializes, and markets cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing in the United States. The company offers the Aurix System, which separates autologous blood to produce a platelet-based therapy for the chronic wound care market. Its customers include hospital outpatient wound care clinics and other private practice physicians treating chronic wounds. The company was formerly known as Cytomedix, Inc. and changed its name to Nuo Therapeutics, Inc. in November 2014. Nuo Therapeutics, Inc. was incorporated in 1998 and is based in Houston, Texas.
Frequently asked questions
What sector does Nuo Therapeutics Inc (AURX) operate in?
Nuo Therapeutics Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Nuo Therapeutics Inc (AURX) current stock price?
As of the latest data, Nuo Therapeutics Inc stock price is $1.00, with a previous close of $1.00.
What is Nuo Therapeutics Inc (AURX) current market capitalization?
Nuo Therapeutics Inc market cap is approximately 48.41 million.
What is Nuo Therapeutics Inc (AURX) Earnings Per Share (EPS)?
The trailing EPS is -$0.04, and the forward EPS is -$0.01.
Does Nuo Therapeutics Inc (AURX) pay dividends?
No. Nuo Therapeutics Inc does not pay a dividend.
What is Nuo Therapeutics Inc (AURX) beta (volatility) score?
Nuo Therapeutics Inc has a beta of -835.777, indicating lower volatility than the overall market.
